A carregar...
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma
PURPOSE: Preclinical data suggest that anti-VEGF agents plus mTOR inhibitors yield synergistic antitumor effects. A phase I trial using a 3+3 dose escalation design of sunitinib (S) plus temsirolimus (T) was stopped after the first dose pair led to 2 of 3 patients experiencing dose-limiting toxicity...
Na minha lista:
| Publicado no: | Clin Genitourin Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4991027/ https://ncbi.nlm.nih.gov/pubmed/25465491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2014.10.004 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|